Comparison of oncologic outcomes of extrahepatic cholangiocarcinoma according to tumor location: perihilar cholangiocarcinoma versus distal bile duct cancer

다국어 초록 (Multilingual Abstract)

Purpose: Extrahepatic cholangiocarcinoma is distinguished into perihilar cholangiocarcinoma (PHC) and distal bile duct cancer (DBC). The studies for each subtype have been conducted separately. This study compared oncological outcomes between PHC and DBC.
Methods: From 2001 to 2017, patients who underwent surgery at Seoul National University Hospital for PHC or DBC were enrolled. T stage was reclassified for tumor extent as ‘confined to’ or ‘beyond’ the bile duct (BD). In survival analysis, stage matching was performed based on tumor extent and lymph node (LN) metastasis.
Results: There were 680 patients enrolled: 295 with PHC and 385 with DBC. The R0 resection rate was higher in DBC (77.3% vs. 89.9%, P = 0.001). Tumors confined to BD were more common in PHC (61.7% vs. 37.7%, P = 0.001). The 5-year survival rate (5YSR) was higher in DBC patients (30.8% vs. 47.8%, P = 0.001). After stage matching, DBC patients showed better 5YSR for tumors confined to BD/LN(–) (47.1% vs. 64.3%), confined to BD/LN(+) (22.0% vs. 35.0%), beyond BD/LN(–) (21.9% vs. 49.8%), and beyond BD/LN(+) (9.6% vs. 26.9%). The overall recurrence rate was higher in PHC (59.7% vs. 51.9%, P = 0.045), with no difference in the recurrence types between two groups. Radiation therapy was effective for patients with advanced stage disease (5YSR: 35.8% vs. 29.5%, P = 0.022); adjuvant chemotherapy was effective for patients receiving R1 resection (5YSR: 37.3% vs. 13.2%, P = 0.040).
Conclusion: Differences were identified in oncological outcomes between PHC and DBC, including pathologic findings and survival outcomes.

참고문헌 (Reference)

1 Wellner UF, "The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection : a metaanalysis for the 5-year survival" 47 : 271-279, 2017

2 Edge SB, "The American Joint Committee on Cancer : the 7th edition of the AJCC cancer staging manual and the future of TNM" 17 : 1471-1474, 2010

3 Akamatsu N, "Surgical strategy for bile duct cancer : advances and current limitations" 2 : 94-107, 2011

4 Reding R, "Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey" 213 : 236-241, 1991

5 Tyson GL, "Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification" 59 : 3103-3110, 2014

6 Sakamoto Y, "Prognostic factors of surgical resection in middle and distal bile duct cancer : an analysis of 55 patients concerning the significance of ductal and radial margins" 137 : 396-402, 2005

7 Hu HJ, "Prognostic factors and longterm outcomes of hilar cholangiocarcinoma : a single-institution experience in China" 22 : 2601-2610, 2016

8 Murakami Y, "Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma" 18 : 651-658, 2011

9 Yoshida T, "Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer" 137 : 69-73, 2002

10 Bird N, "Meta-analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma" 105 : 1408-1416, 2018

11 Waseem D, "Intrahepatic, perihilar and distal cholangiocarcinoma : management and outcomes" 16 : 133-139, 2017

12 Ercolani G, "Intrahepatic, peri-hilar and distal cholangiocarcinoma : three different locations of the same tumor or three different tumors?" 41 : 1162-1169, 2015

13 Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries" 68 : 394-424, 2018

14 Esnaola NF, "Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma" 122 : 1349-1369, 2016

15 Al Mahjoub A, "Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population" 31 : 678-684, 2019

16 Ke Q, "Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis" 17 : 211-, 2019

17 Seyama Y, "Current surgical treatment for bile duct cancer" 13 : 1505-1515, 2007

18 Shin HR, "Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma : focus on East and South-Eastern Asia" 11 : 1159-1166, 2010

19 Razumilava N, "Classification, diagnosis, and management of cholangiocarcinoma" 11 : 13-21, 2013

20 Boris Blechacz, "Cholangiocarcinoma: Current Knowledge and New Developments" 거트앤리버 소화기연관학회협의회 11 (11): 13-26, 2017

21 Nakeeb A, "Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors" 224 : 463-473, 1996

22 DeOliveira ML, "Cholangiocarcinoma : thirty-one-year experience with 564 patients at a single institution" 245 : 755-762, 2007

23 Hoehn RS, "Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma" 22 (22): S1133-S1139, 2015

24 Kim K, "Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer : a long-term single center experience" 35 : 136-140, 2012

25 Jang JY, "Actual long-term outcome of extrahepatic bile duct cancer after surgical resection" 241 : 77-84, 2005